Comparison of Photocoagulation With Combined Intravitreal Triamcinolone for Diabetic Macular Edema
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To compare the efficacy between macular laser grid (MLG) photocoagulation and MLG plus intravitreal triamcinolone acetonide (IVTA; MLG+IVTA) therapy in diabetic macular edema (DME) patients. Methods: A prospective, randomized, clinical trial was conducted of DME patients. A total of 60 eyes (54 patients) affected by DME were observed for a minimum of 6 months. Thirty eyes of 28 patients who received MLG treatment and 30 eyes of 26 patients who received the combined MLG+IVTA treatment were included in the study. Main outcome measures were BCVA and central macular thickness (CMT) as measured by optical coherence tomography (OCT) at 1, 3, and 6 months after treatment. Additionally, the authors examined retrospectively 20 eyes of 20 patients who were treated with only IVTA and compared with the 2 groups (MLG group and MLG+IVTA group). Results: Baseline BCVA was 0.53±0.32 and CMT was 513.9±55.1 ㎛ in the MLG group. At 1 and 3 months after treatment, the MLG group showed no significant improvement of BCVA and CMT, although there was significant improvement after 6 months. In the MLG+IVTA group, the baseline BCVA was 0.59±0.29 and CMT was 498.2±19.8 ㎛. After treatment, significant improvement of BCVA and CMT was observed at all follow-up time periods. When comparing the MLG group with the MLG+IVTA group, the latter had better results after 1 and 3 months, although at 6 months, there was no significant difference of BCVA and CMT between the 2 groups. Additionally, the IVTA group showed more improvement than the MLG group at 1 and 3 months but showed no significant difference at 6 months. In addition, the IVTA group showed no significant difference with the MLG+IVTA group at all follow-up time periods. Conclusions: For DME patients, the combined MLG+IVTA treatment had a better therapeutic effect than the MLG treatment for improving BCVA and CMT at the early follow-up time periods. IVTA treatment alone could be an additional alternative therapeutic option to combined therapy.
Abstract
Purpose: To compare the efficacy between macular laser grid (MLG) photocoagulation and MLG plus intravitreal triamcinolone acetonide (IVTA; MLG+IVTA) therapy in diabetic macular edema (DME) patients. Methods: A prospective, randomized, clinical trial was conducted of DME patients. A total of 60 eyes (54 patients) affected by DME were observed for a minimum of 6 months. Thirty eyes of 28 patients who received MLG treatment and 30 eyes of 26 patients who received the combined MLG+IVTA treatment were included in the study. Main outcome measures were BCVA and central macular thickness (CMT) as measured by optical coherence tomography (OCT) at 1, 3, and 6 months after treatment. Additionally, the authors examined retrospectively 20 eyes of 20 patients who were treated with only IVTA and compared with the 2 groups (MLG group and MLG+IVTA group). Results: Baseline BCVA was 0.53±0.32 and CMT was 513.9±55.1 ㎛ in the MLG group. At 1 and 3 months after treatment, the MLG group showed no significant improvement of BCVA and CMT, although there was significant improvement after 6 months. In the MLG+IVTA group, the baseline BCVA was 0.59±0.29 and CMT was 498.2±19.8 ㎛. After treatment, significant improvement of BCVA and CMT was observed at all follow-up time periods. When comparing the MLG group with the MLG+IVTA group, the latter had better results after 1 and 3 months, although at 6 months, there was no significant difference of BCVA and CMT between the 2 groups. Additionally, the IVTA group showed more improvement than the MLG group at 1 and 3 months but showed no significant difference at 6 months. In addition, the IVTA group showed no significant difference with the MLG+IVTA group at all follow-up time periods. Conclusions: For DME patients, the combined MLG+IVTA treatment had a better therapeutic effect than the MLG treatment for improving BCVA and CMT at the early follow-up time periods. IVTA treatment alone could be an additional alternative therapeutic option to combined therapy.
참고문헌 (22)
- Stephen J. Ryan, "Nonproliferative diabetic retinopathy" (2006), Mosby, Elsevier Inc.
- Photocoagulation for diabetic macular edema, "Early Treatment Diabetic Retinopathy Study Report Number 1. Early Treatment Diabetic Retinopathy Study Research Group", Arch Ophthalmol, 103, pp.1796~1806 (1985)
- atment techniques and clinical guidelines for photocoagulation of diabetic macular edema, "Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group", Ophthalmology, 94, pp.761~774 (1987)
- Focal photocoagulation treatment of diabetic macular edema, "Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group", Arch Ophthalmol, 113, pp.1144~1155 (1995)
- Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema", Ophthalmology, 109, pp.920~927 (2002)
- Jonas JB, "Intravitreal injection of triamcinolone for diffuse diabetic macular edema", Arch Ophthalmol, 121, pp.57~61 (2003)
- Massin P, "Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial", Ophthalmology, 111, pp.218~224 (2004)
- Jonas JB, "Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study", Br J Ophthalmol, 89, pp.321~326 (2005)
- Ozkiris A, "Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema", Eur J Ophthalmol, 14, pp.543~549 (2004)
- Sutter FK, "Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three- month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial", Ophthalmology, 111, pp.2044~2049 (2004)
- Micelli Ferrari T, "Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema", Eur J Ophthalmol, 14, pp.321~324 (2004)
- Floman N, "Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production", Invest Ophthalmol Vis Sci, 16, pp.69~73 (1977)
- Wilson CA, "Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation", Arch Ophthalmol, 110, pp.1155~1159 (1992)
- Antcliff RJ, "Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study", Ophthalmology, 108, pp.765~772 (2001)
- Schindler RH, "The clearance of intravitreal triamcinolone acetonide", Am J Ophthalmol, 93, pp.415~417 (1982)
- Beer PM, "Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection", Ophthalmology, 110, pp.681~686 (2003)
- Kyung Seek Choi, "Laser Photocoagulation Combined with Intravitreal Triamcinolone Acetonide Injection in Proliferative Diabetic Retinopathy with Macular Edema", Korean Journal of Ophthalmology, 21(1), pp.11~17 (2007), 대한안과학회
- 정윤철, "당뇨황반부종의 종류에 따른 유리체강내 스테로이드주입술과 국소레이저 치료의 효과 비교", 대한안과학회지, 48(5), pp.655~664 (2007), 대한안과학회
- Wingate RJ, "Intravitreal triamcinolone and elevated intraocular pressure", Aust N Z J Ophthalmol, 27, pp.431~432 (1999)
- Moshfeghi DM, "Acute endophthalmitis following intravitreal triamcinolone acetonide injection", Am J Ophthalmol, 136, pp.791~796 (2003)
- Nelson ML, "Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection", Retina, 23, pp.686~691 (2003)
- Thomas ER, "Intravitreal triamcinolone acetonide concentration after subtenon injection", Am J Ophthalmol, 142, pp.860~861 (2006)